Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026)

Vireo Growth (VREOF) reported Depreciation & Amortization (CF) of $4.0 million for Q1 2026, up 566.67% on a YoY basis from $600000.0 in Q1 2025, and down 66.43% sequentially from $11.9 million in Q4 2025.

Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $4.0 million in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 566.67% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $19.5 million (up 679.43% YoY), and the FY2025 full-year result was $16.1 million, up 535.04% from the prior year.
  • Depreciation & Amortization (CF) retreated to $4.0 million in Q1 2026, from $11.9 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $11.9 million in Q4 2025 to a low of $600000.0 in Q1 2025.
  • A 5-year average of $1.7 million and a median of $776991.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
  • Across the five-year window, Depreciation & Amortization (CF) slipped 29.08% in 2024 and jumped 1774.66% in 2025, its largest moves.
  • Tracing VREOF's Depreciation & Amortization (CF) over 5 years: stood at $889195.0 in 2022, then dropped by 26.84% to $650503.0 in 2023, then retreated by 2.29% to $635583.0 in 2024, then jumped by 1774.66% to $11.9 million in 2025, then slumped by 66.43% to $4.0 million in 2026.
  • Business Quant data shows VREOF's Depreciation & Amortization (CF) at $4.0 million in Q1 2026, $11.9 million in Q4 2025, and $2.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 239.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 119.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 1.04 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 22.60 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 676.10 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 7.20 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 172.00 Mn
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn 4.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 4.00 Mn
Mar 31, 2026 4.00 Mn
Dec 31, 2025 11.92 Mn
Dec 31, 2025 11.92 Mn
Sep 30, 2025 2.34 Mn
Sep 30, 2025 2.34 Mn
Jun 30, 2025 1.25 Mn
Jun 30, 2025 1.25 Mn
Mar 31, 2025 600,000.00
Mar 31, 2025 600,000.00
Dec 31, 2024 635,583.00
Dec 31, 2024 635,583.00
Sep 30, 2024 633,586.00
Sep 30, 2024 633,586.00
Jun 30, 2024 633,884.00
Jun 30, 2024 633,884.00
Mar 31, 2024 633,728.00
Mar 31, 2024 633,728.00
Dec 31, 2023 650,503.00
Dec 31, 2023 650,503.00